Serotonin antidepressants and atrial fibrillation burden from cardiac implantable electronic devices

Abstract

Objective: Depression and anxiety show a bidirectional relationship with atrial fibrillation (AF). Antidepressant use is associated with a reduction in the incidence of AF. However, no studies have examined the relationship between antidepressant use and AF burden (time in AF). This retrospective cohort study examined cardiac implantable device-detected AF episodes and their relationship with antidepressant use, among other treatment factors. Methods: Consecutive patients from the Western Health Cardiology Department attending pacemaker checks between 2015 and 2021 were included. Patients with permanent AF were excluded, yielding 285 patients with no or paroxysmal AF, with a total of 772 patient encounters. Generalized estimating equations were used to model two processes: binary AF (present/absent) and the number of days in AF for patients with AF. Results: Each yearly increase with age was associated with an increase in the odds of developing AF (OR 1.03 [1.00–1.05], p =.027). Male gender conferred a reduction in AF incidence (OR 0.30 [0.13–0.68], p =.004). Digoxin use was associated with incident AF (OR 4.43 [1.07–18.4], p =.04). Sotalol and heart-failure beta blocker use were associated with a decrease in AF burden (IRR 0.30 [0.12–0.78], p =.013 and 0.33 [0.14–0.81], p =.015). Selective serotonin reuptake inhibitor antidepressant use was associated with reduced AF burden (IRR 0.27 [0.09–0.81], p =.019), as was selective serotonin/noradrenaline reuptake inhibitor use (IRR 0.07 [0.03–0.15], p